Back
Cidara Therapeutics Quote, Financials, Valuation and Earnings
Sponsored
CDTX
Sponsored
Yours Free! Top SIX AI Dividend Stocks Right Now
NO CREDIT CARD REQUIRED!
Buy
62
CDTX
Cidara Therapeutics
Last Price:
13.12
Seasonality Move:
7.06%
7 Day Trial
ALL ACCESS PASS
$
7
The Mysterious VC Firm Behind Nvidia's Secret Weapon
Details Here!Cidara Therapeutics Price Quote
$13.12
+0.09 (+0.69%)
(Updated: November 5, 2024 at 9:50 AM ET)
Cidara Therapeutics Key Stats
Buy
62
Cidara Therapeutics (CDTX)
is a Buy
Day range:
$13.00 - $13.45
52-week range:
$10.00 - $24.40
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
1.51
P/B ratio:
0.7%
Volume:
20.2K
Avg. volume:
18.7K
1-year change:
-19.57%
Market cap:
$91.7M
Revenue:
$63.9M
EPS:
$-25.27
How Much Does Cidara Therapeutics Make?
-
How Much Are Cidara Therapeutics's Sales Annually?
CDTX Revenues are $63.9M -
How Much Profit Does Cidara Therapeutics's Make A Year?
CDTX net income is -$22.9M
Is Cidara Therapeutics Growing As A Company?
-
What Is Cidara Therapeutics's Growth Rate Quarterly?
Quarterly YoY revenue growth is -0.94% -
What Is Cidara Therapeutics's EPS Quarterly YoY Growth Rate?
Quarterly, year-over-year diluted EPS growth rate is 0%
Cidara Therapeutics Stock Price Performance
-
Did Cidara Therapeutics Stock Go Up Last Month?
Cidara Therapeutics share price went up by 19.54% last month -
Did CDTX's Share Price Rise Over The Last Year?
CDTX share price fell by -19.57% over the past 1 year
What Is Cidara Therapeutics 52-Week High & Low?
-
What Is Cidara Therapeutics’s 52-Week High Share Price?
Cidara Therapeutics has traded as high as $24.40 over the past 52 weeks -
What Is Cidara Therapeutics’s 52-Week Low Share Price?
Cidara Therapeutics has traded as low as $10.00 over the past 52 weeks
Cidara Therapeutics Price To Free Cash Flow
Data Unavailable
Is It Risky To Buy Cidara Therapeutics?
-
How Much Debt Does Cidara Therapeutics Have?
Total long term debt quarterly is $0 -
How Much Cash Does Cidara Therapeutics Have?
Cash and short term investments quarterly total is $164.4M -
What Is Cidara Therapeutics’s Book Value Per Share?
Book value per share is 28.66
Is Cidara Therapeutics Cash Flow Positive?
-
What Is CDTX Cash Flow From Operations?
Cash flow from operations (TTM) is -$124.8M -
What Is Cidara Therapeutics’s Cash Flow From Financing?
Cash flow from financing (TTM) is $239M -
What Is Cidara Therapeutics’s Cash Flow From Investing?
Cash flow from investing (TTM) is -$327K
Cidara Therapeutics Return On Invested Capital
-
Is Management Doing A Good Job?
CDTX return on invested capital is -449.07% -
What Is Cidara Therapeutics Return On Assets?
ROA measures how assets are converting to revenues and is -135.81% -
What Is CDTX Return On Equity?
ROE is a measure of profitability and is -449.07%
Cidara Therapeutics Earnings Date & Stock Price
-
What Is Cidara Therapeutics's Stock Price Today?
A single share of CDTX can be purchased today for 13.03 -
What Is Cidara Therapeutics’s Stock Symbol?
Cidara Therapeutics trades on the nasdaq under the ticker symbol: CDTX -
When Is Cidara Therapeutics’s Next Earnings Date?
The next quarterly earnings date for Cidara Therapeutics is scheduled on April 22, 2025 -
When Is CDTX's next ex-dividend date?
Cidara Therapeutics's next ex-dividend date is May 1, 2020 -
How To Buy Cidara Therapeutics Stock?
You can buy Cidara Therapeutics shares by opening an account at a top tier brokerage firm, such as TD Ameritrade or tastyworks.
Cidara Therapeutics Competitors
-
Who Are Cidara Therapeutics's Competitors?
Below is a list of companies who compete with Cidara Therapeutics or are related in some way:
Cidara Therapeutics Dividend Yield
-
What Is CDTX Dividend Yield?
Cidara Therapeutics’s dividend yield currently is 0% -
What Is Cidara Therapeutics’s Payout Ratio?
Cidara Therapeutics’s payout ratio is 0% -
When Did Cidara Therapeutics Last Pay A Dividend?
The latest dividend pay date is November 5, 2024 -
What Is Cidara Therapeutics’s Dividend Per Share?
Cidara Therapeutics pays a dividend of $0.00 per share
Cidara Therapeutics Analyst Estimates
YoY Growth | Past Surprise | |
---|---|---|
EPS: | 0% | -556.6% |
Revenue: | -94.07% | -76.77% |
Analyst Recommendations
Buy Recommendations: | 1 |
---|---|
Hold Recommendations: | 0 |
Sell Recommendations: | 0 |
Price Target: | 24.50 |
Upside from Last Price: | 88.03% |